Clinically Tolerated Strategies for NMDA Receptor Antagonism
Vincent Chen H, Zhang D, Lipton S. Clinically Tolerated Strategies for NMDA Receptor Antagonism. The Receptors 2008, 327-361. DOI: 10.1007/978-1-59745-055-3_8.Peer-Reviewed Original ResearchExcessive NMDAR activityNMDAR activityClinical trialsGlutamate receptorsSide effectsNeurologic disordersNervous systemAcute hypoxic-ischemic brain injuryGeneralized inhibitionAlzheimer's diseaseSecond-generation memantine derivativesHypoxic-ischemic brain injuryPhase 3 clinical trialsExcessive NMDAR activationSevere neuropathic painExcitatory amino acidsGlutamate-mediated neurotoxicityGlutamate receptor subtypesChronic neurodegenerative diseasesSystemic side effectsMajor excitatory transmitterNormal functionNMDA receptor antagonismGreater neuroprotective propertiesCentral nervous system